Clinical trial
A Phase 2a Study to Evaluate the Effects of DaxibotulinumtoxinA for Injection on the Treatment of Dynamic Forehead Lines and Glabellar Lines
NCT06411002 is registered in ClinicalTrials.gov with Revance Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a Study to Evaluate the Effects of DaxibotulinumtoxinA for Injection on the Treatment of Dynamic Forehead Lines and Glabellar Lines
- Lead sponsor
- Revance Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 8, 2024
- Completion date
- February 12, 2025
- Enrollment
- 27 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
glabellar frown lines